Literature DB >> 11406947

[Increased iris pigmentation after use of latanoprost in Japanese brown eyes].

T Hara1.   

Abstract

PURPOSE: To evaluate the incidence of the increased iris pigmentation in Japanese with topical latanoprost.
MATERIAL AND METHODS: One hundred and twelve patients who had homogeneous brown irises were studied. Age of the patients was 23 to 80(average 63.8 +/- 10.4) and follow-up periods were 6 to 12 (10.3 +/- 1.4) months. Slit lamp examination was carefully performed before use and at every month after use of latanoprost. Photographs were taken when necessary. The Kaplan-Meier life table method was used to evaluate the incidence of the increased iris pigmentation. RESULT: Iris pigment increase was observed in 47 patients. The incidence of the increased iris pigmentation was calculated as 10.1% at 3 months, 26.4% at 6 months, 50.1% at 9 months and 51.6% at 12 months after use. Pigmentation progressed as a granular concentric or sunrise pattern or a subtype of these. Some pigmentation occurred at one month after use, and progressed monthly. No patients noted their own iris color change, but were told by their relatives. Iris color changes of brown iris were considered to be less strong than in the hazel(green or blue/gray or yellow combined with brown) eye.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406947

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  5 in total

1.  Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.

Authors: 
Journal:  Jpn J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.447

2.  Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.

Authors:  T Chiba; K Kashiwagi; N Chiba; K Ishijima; M Furuichi; S Kogure; K Abe; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

3.  Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.

Authors:  Takaiko Yoshino; Takeo Fukuchi; Tetsuya Togano; Masaaki Seki; Hiroko Ikegaki; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

Review 4.  Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.

Authors:  Murray Fingeret; Ian B Gaddie; Marc Bloomenstein
Journal:  Clin Exp Optom       Date:  2019-01-07       Impact factor: 2.742

5.  Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.

Authors:  Kazuhide Kawase; Jason L Vittitow; Robert N Weinreb; Makoto Araie
Journal:  Adv Ther       Date:  2016-07-25       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.